Colleen Loo

Colleen Loo is a clinical researcher specialising in rapid-acting antidepressant therapies, with a particular focus on ketamine and its stereoisomers. Her work centres on translating mechanistic psychopharmacology into scalable clinical interventions: she has led and co-authored multiple randomised, double-blind, active-controlled trials and pilot studies assessing subcutaneous and intravenous ketamine, arketamine, and extended‑release oral ketamine formulations for treatment-resistant depression. Loo's research also examines the anxiolytic effects of ketamine, safety and tolerability of repeated dosing regimens, and economic considerations for implementation of subcutaneous administration in routine care.

Her contributions emphasise methodological rigour in clinical trial design, safety monitoring, and comparative effectiveness across administration routes and formulations. Through these studies she has helped clarify clinical efficacy signals, short-term safety profiles, and pragmatic aspects of delivering ketamine-based treatments for depressive and anxiety disorders, informing both clinical practice and future development of rapid-acting antidepressant medicines.